Response-Adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed by Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Lymphoma After First-Line Immunochemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Response-Adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed by Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Lymphoma After First-Line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial
Cancer Med 2019 Oct 01;[EPub Ahead of Print], FJ Peñalver, JA Márquez, S Durán, P Giraldo, A Martín, C Montalbán, JM Sancho, MJ Ramírez, MJ Terol, FJ Capote, A Gutiérrez, B Sánchez, A López, A Salar, G Rodríguez-Caravaca, M Canales, MD CaballeroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.